CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top player positioning

3.3. Market dynamics

3.3.1. Drivers

3.3.1.1. Rise in incidence of cancer across the globe
3.3.1.2. Surge in global geriatric population
3.3.1.3. Increase in healthcare expenditure worldwide

3.3.2. Restraints

3.3.2.1. Adverse effects associated with the use of drugs employed in cancer pain management

3.3.3. Opportunities

3.3.3.1. Increase in number of pipeline drugs
3.3.3.2. Growth opportunities in emerging markets

3.3.4. Impact analyses

CHAPTER 4: CANCER PAIN MARKET, BY DRUG TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Opioids

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Morphine

4.2.2.1.1. Market size and forecast

4.2.2.2. Fentanyl

4.2.2.2.1. Market size and forecast

4.2.2.3. Others

4.2.2.3.1. Market size and forecast

4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country

4.3. Non-opioids

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type

4.3.2.1. Acetaminophen

4.3.2.1.1. Market size and forecast

4.3.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

4.3.2.2.1. Market size and forecast

4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country

4.4. Nerve blockers

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

CHAPTER 5: CANCER PAIN MARKET, BY DISEASE INDICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Lung cancer

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Colorectal cancer

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Breast cancer

5.4.1. Market size and forecast
5.4.2. Market analysis, by country

5.5. Prostate cancer

5.5.1. Market size and forecast
5.5.2. Market analysis, by country

5.6. Blood cancer

5.6.1. Market size and forecast
5.6.2. Market analysis, by country

5.7. Others

5.7.1. Market size and forecast
5.7.2. Market analysis, by country

CHAPTER 6: CANCER PAIN MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. market size and forecast, by type
6.2.2.1.2. U.S. market size and forecast, by disease indication

6.2.2.2. Canada

6.2.2.2.1. Canada market size and forecast, by type
6.2.2.2.2. Canada market size and forecast, by disease indication

6.2.2.3. Mexico

6.2.2.3.1. Mexico market size and forecast, by type
6.2.2.3.2. Mexico market size and forecast, by disease indication

6.2.3. Market size and forecast, by type
6.2.4. Market size and forecast, by disease indication

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany market size and forecast, by type
6.3.2.1.2. Germany market size and forecast, by disease indication

6.3.2.2. France

6.3.2.2.1. France market size and forecast, by type
6.3.2.2.2. France market size and forecast, by disease indication

6.3.2.3. UK

6.3.2.3.1. UK market size and forecast, by type
6.3.2.3.2. UK market size and forecast, by disease indication

6.3.2.4. Italy

6.3.2.4.1. Italy market size and forecast, by type
6.3.2.4.2. Italy market size and forecast, by disease indication

6.3.2.5. Spain

6.3.2.5.1. Spain market size and forecast, by type
6.3.2.5.2. Spain market size and forecast, by disease indication

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe market size and forecast, by type
6.3.2.6.2. Rest of Europe market size and forecast, by disease indication

6.3.3. Market size and forecast, by type
6.3.4. Market size and forecast, by disease indication

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan market size and forecast, by type
6.4.2.1.2. Japan market size and forecast, by disease indication

6.4.2.2. China

6.4.2.2.1. China market size and forecast, by type
6.4.2.2.2. China market size and forecast, by disease indication

6.4.2.3. Australia

6.4.2.3.1. Australia market size and forecast, by type
6.4.2.3.2. Australia market size and forecast, by disease indication

6.4.2.4. India

6.4.2.4.1. India market size and forecast, by type
6.4.2.4.2. India market size and forecast, by disease indication

6.4.2.5. Rest of Asia-Pacific

6.4.2.5.1. Rest of Asia- Pacific market size and forecast, by type
6.4.2.5.2. Rest of Asia- Pacific market size and forecast, by disease indication

6.4.3. Market size and forecast, by type
6.4.4. Market size and forecast, by disease indication

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil market size and forecast, by type
6.5.2.1.2. Brazil market size and forecast, by disease indication

6.5.2.2. Saudi Arabia

6.5.2.2.1. Saudi Arabia market size and forecast, by type
6.5.2.2.2. Saudi Arabia market size and forecast, by disease indication

6.5.2.3. South Africa

6.5.2.3.1. South Africa market size and forecast, by type
6.5.2.3.2. South Africa market size and forecast, by disease indication

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA market size and forecast, by type
6.5.2.4.2. Rest of LAMEA market size and forecast, by disease indication

6.5.3. Market size and forecast, by type
6.5.4. Market volume and forecast, by disease indication

CHAPTER 7: COMPANY PROFILES

7.1. AOXING PHARMACEUTICAL COMPANY, INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance

7.2. BIODELIVERY SCIENCES INTERNATIONAL, INC.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance

7.3. DAIICHI SANKYO CO., LTD.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product Portfolio
7.3.4. Business performance
7.3.5. Key strategic moves and developments

7.4. GRNENTHAL PHARMA GmbH & CO. KG

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Product Portfolio

7.5. HISAMITSU PHARMACEUTICAL CO., INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance

7.6. INSYS THERAPEUTICS, INC.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance

7.7. MUNDIPHARMA INTERNATIONAL LIMITED

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Product Portfolio

7.8. OREXO AB

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance

7.9. PFIZER INC.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance

7.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance